PCV13: Effective Against First-Episode CAP in Older Adults

Respiratory Tripledemic 2022-23: An Expert Recap

The agency estimates that limiting nicotine levels could lead to 1.8 million fewer tobacco-related deaths by 2060 and health care savings of $1.1 trillion a year over the next 40 years.

April 6th 2023

FDA Updates RSV Vaccine Labels to Include Guillain-Barré Syndrome Warning

William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.

January 8th 2025

NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half

The FDA approved the addition of Guillain-Barré syndrome warnings for Abrysvo and Arexvy, citing postmarketing data suggesting an increased risk.

May 20th 2022

Sanofi Investigational COVID-19/Influenza Combination Vaccines Granted FDA Fast-Track Designation

In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.

Grace Halsey

US Adults Lagging in Flu, COVID-19, and RSV Vaccination: Daily Dose

The 2 novel vaccine candidates each combine a Sanofi licensed influenza vaccine with the Novavax adjuvanted recombinant COVID-19 vaccine.

FDA Proposed Rule Would Limit Nicotine Content in Cigarettes, Cigars, Other Combusted Products

Your daily dose of the clinical news you may have missed.

Related Content

Richard Payerchin

January 16th 2025

Respiratory Tripledemic 2022-23: An Expert Recap

The agency estimates that limiting nicotine levels could lead to 1.8 million fewer tobacco-related deaths by 2060 and health care savings of $1.1 trillion a year over the next 40 years.

April 6th 2023

FDA Updates RSV Vaccine Labels to Include Guillain-Barré Syndrome Warning

William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.

January 8th 2025

NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half

The FDA approved the addition of Guillain-Barré syndrome warnings for Abrysvo and Arexvy, citing postmarketing data suggesting an increased risk.

May 20th 2022

Sanofi Investigational COVID-19/Influenza Combination Vaccines Granted FDA Fast-Track Designation

In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.

Grace Halsey

US Adults Lagging in Flu, COVID-19, and RSV Vaccination: Daily Dose

The 2 novel vaccine candidates each combine a Sanofi licensed influenza vaccine with the Novavax adjuvanted recombinant COVID-19 vaccine.